Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 2 6Phase 3 3Phase 1 2Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Completed 7Unknown 4Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 302Thoracic 234Lymphoid 209Other solid neoplasm 203Other hematologic neoplasm 172Genitourinary 167Breast 146Gynecologic 121CNS 116Dermatologic 87Head & Neck 84Plasma cell 77Sarcoma 61Tumor-Agnostic 56Myeloid 39Endocrine 25NET 13Classical hematology 9Other neoplasm 1Other 1

Conditions

Non-Malignant Neoplasm 1

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Other neoplasm × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡